Jalyn FDA Approval History
FDA Approved: Yes (First approved June 14, 2010)
Brand name: Jalyn
Generic name: dutasteride and tamsulosin
Dosage form: Capsules
Company: GlaxoSmithKline
Treatment for: Benign Prostatic Hyperplasia
Jalyn is a combination of dutasteride (5α-reductase inhibitor) and tamsulosin (alpha-adrenergic antagonist) indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
Development timeline for Jalyn
| Date | Article |
|---|---|
| Jun 14, 2010 | Approval FDA approves Jalyn, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
